Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).

被引：0
|
作者：
Garcia-Manero, Guillermo
Yang, Allen S.
Giles, Francis
Faderl, Stefan
Ravandi, Farhad
Cortes, Jorge
Newsome, Willie M.
Issa, Jean-Pierre
Patterson, Tracy-Ann
Dubay, Marja
Li, Zuomei
Kantarjian, Hagop
Martell, Robert E.
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ So Calif, Norris Comprehens Canc Ctr, Div Hematol, Los Angeles, CA USA
[3] MethylGene Inc, Montreal, PQ, Canada
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1954
引用
收藏
页码：552A / 553A
页数：2
相关论文
共 50 条
  • [41] Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS)
    Garcia-Manero, G
    Issa, JP
    Cortes, J
    Koller, C
    O'brien, S
    Estey, E
    Canalli, AA
    Chiao, J
    Richon, V
    Kantarjian, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 201S - 201S
  • [42] Intravenous voriconazole (IV-VORI) prevents invasive fungal infections (IFI) in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Mattiuzzi, GN
    Alvarado, G
    Kantarjian, HM
    Verstovsek, S
    Cabanillas, M
    Faderl, S
    Lim, JT
    Giles, F
    Beran, M
    O'Brien, S
    Estey, EH
    BLOOD, 2004, 104 (11) : 253A - 253A
  • [43] A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas
    Crump, Michael
    Andreadis, Charalambos
    Assouline, Sarit E.
    Rizzieri, David
    Copeland, Amanda
    Van Der Jagt, Richard H. C.
    Fox, Susan
    Reid, Gregory K.
    Besterman, Jeffrey M.
    Martell, Robert E.
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Phase II study of VNP40101M in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplasia (MIDS).
    Giles, FJ
    O'Brien, S
    Vey, N
    Feldman, E
    Rizzieri, D
    Khan, KD
    Bilgrami, SF
    Verhoef, G
    Mufti, G
    Johnson, B
    Karp, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 570S - 570S
  • [45] Hospitalization rates in elderly, newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients treated with azacitidine.
    Ueda, Masumi
    Gupta, Divya
    Caimi, Paolo Fabrizio
    Creger, Richard
    Little, Jane
    William, Basem M.
    Lazarus, Hillard M.
    De Lima, Marcos J. G.
    Cooper, Brenda W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Ghanem, H.
    Kantarjian, H.
    Garcia-Manero, G.
    Ravandi, F.
    Faderl, S.
    Cortes, J. E.
    Reyes, A.
    O'Brien, S. M.
    Borthakur, G.
    Kadia, T. M.
    Burger, J. A.
    Konopleva, M.
    Jabbour, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Phase I trials of the oral histone deacetylase (HOAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors
    Gelmon, K
    Tolcher, A
    Carducci, M
    Reid, GK
    Li, Z
    Kalita, A
    Callejas, V
    Longstreth, J
    Besterman, JM
    Siu, LL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 228S - 228S
  • [48] Phase II Study of 5-Azacitidine and Vorinostat In Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance or Presence of Other comorbidities
    Garcia-Manero, Guillermo
    Estey, Elihu H.
    Jabbour, Elias
    Kadia, Tapan
    Estrov, Zeev
    Cortes, Jorge
    Boone, Patricia Ann
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 266 - 266
  • [49] A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
    Ong, Faustine
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Alvarado, Yesid
    Ohanian, Maro
    Konopleva, Marina
    Jabbour, Elias
    Jain, Nitin
    Borthakur, Gautam
    DiNardo, Courtney D.
    Daver, Naval
    Issa, Ghayas C.
    Sasaki, Koji
    Chien, Kelly S.
    Takahashi, Koichi
    Andreeff, Michael
    Muftuoglu, Muharrem
    Delumpa, Ricardo
    Mayor, Ejiroghene
    Loiselle, Christopher
    Waller, Lourdes
    Banks, Glenda
    Kantarjian, Hagop
    Cortes, Jorge E.
    Short, Nicholas
    BLOOD, 2022, 140 : 6206 - 6208
  • [50] Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Morita, Kiyomi
    Naqvi, Kiran
    Montalban, Guillermo
    Thompson, Philip A.
    Takahashi, Koichi
    Alvarado, Yesid
    Jabbour, Elias
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
12345